Table 2 Characteristics for patient profiles analysed in stage 1 of the WWARN PCE^a

Number of parasite measurements

 Median, IQR

5, 5–6

6, 5–7

3, 3–3

 Range

3–14

3–14

3–5

 < 3

0

0

0

 3

37 (5.2%)

2 (0.3%)

35 (97.2%)

 4

107 (15%)

107 (15.8%)

0

 5

217 (30.4%)

216 (31.9%)

1 (2.8%)

 6

182 (25.5%)

182 (26.8%)

0

 7

110 (15.4%)

110 (16.2%)

0

 ≥ 8

61 (8.5%)

61 (9%)

0

Sex

 Female

135 (18.9%)

128 (18.9%)

7 (19.4%)

 Male

579 (81.1%)

550 (81.1%)

29 (80.6%)

Age (years)

 Median, IQR

35, 24–49

34, 23–48

37, 23–44.5

 Range

3–96

3–96

14–68

Weight (kg)

 Median, IQR

58, 50–67

58, 50.4–67

59, 51.5–68

 Range

11–118

11–118

35–80.5

Previous malaria

 No

511 (71.6%)

489 (72.1%)

22 (61.1%)

 Yes

203 (28.4%)

189 (27.9%)

14 (38.9%)

Days of preceding fever

 Median, IQR

4, 3–7

4, 3–7

4, 3–7

 Range

0–44^b

0–44^c

2–14^d

Initial parasitaemia (/μL of blood)

 Median, IQR

1898, 463–6276

2056, 533–6398

127, 56–555

 Range

28–325,294

28–325,294

28–16,748

Treatment

Uncomplicated malaria

 Artemether–lumefantrine

320 (44.8%)

301 (44.3%)

19 (52.8%)

 Artesunate–mefloquine

115 (16.1%)

111 (16.4%)

4 (11%)

 Chloroquine

176 (24.7%)

174 (25.7%)

2 (5.6%)

Severe malaria

 Artemether–lumefantrine followed by artesunate (intravenous)

16 (2.2%)

15 (2.2%)

1 (2.8%)

 Artesunate (intravenous) followed by artemether–lumefantrine

87 (12.2%)

77 (11.4%)

10 (27.8%)